Effect of Sarcopenia on the Occurrence of Toxicity Related to Anti-cancer Treatments

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

700 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-06-24

Study Completion Date

2028-05-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to learn about the effect of sarcopenic status on the occurrence of treatment-related toxicity during the first course of anti-cancer treatment in several types of cancers.

The main question it aims to answer is :

Is sarcopenia a predictive marker for the occurrence of toxicity in the initial phase of cancer treatment?

The evaluation will focus on the body composition of the participants, assessed by impedancemetry, and on their muscular performance by standardized physical tests.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Development of an Evaluation Method of Elderly Condition in Patient Receiving Chemotherapy Treatment

NCT00210249

Lymphoma Digestive System Diseases Ovarian Diseases +3 more

COMPLETED

Multimodal Intervention for Cachexia in Advanced Cancer Patients Undergoing Chemotherapy

NCT02330926

Cachexia Neoplasms

COMPLETED PHASE3

Open Labeled Placebo in Reducing Cancer Related Fatigue in Patients With Advanced Cancer

NCT03927885

Advanced Malignant Solid Neoplasm Metastatic Malignant Solid Neoplasm Recurrent Malignant Solid Neoplasm

ACTIVE_NOT_RECRUITING PHASE2/PHASE3

Prevention of Sagopilone-induced Neurotoxicity With Acetyl-L-Carnitine (ALC)

NCT00751205

Prostate Cancer Ovarian Cancer

COMPLETED PHASE2

Malnutrition and Sarcopenia Screening in Chemotherapy Patients

NCT07163286

Nutrition Aspect of Cancer Sarcopenia Chemotherapeutic Agent Toxicity

ACTIVE_NOT_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The present study is single-center within the Centre Hospitalier Metropole Savoie, interventional and prospective, and will be carried out in patients suffering from cancer and having received an indication for systemic oncological treatment, in first line,

The inclusion visit (V1) will take place during the first chemotherapy session and will include study-specific measurements for the assessment of sarcopenia (impedancemetry, grip strength and chair rise test) as well as the distribution of actimeters to patients. The duration of these examinations carried out in addition to clinical practice is estimated at 15 minutes and does not involve any particular risks for patients.

Data collection 1 (R1) will be carried out during the second course of chemotherapy, data collection 2 (R2) will be carried out 6 months from the start of treatment, and data collection 3 (R3) at 12 months from the start of treatment. inclusion, based on standardized extraction of the medical file.

An exploratory study will be offered to patients treated in the context of adjuvant or neoadjuvant breast cancer and treated by the AC/PACLITAXEL protocol which will involve a second optional visit (optional V1.1) during the first injection of PACLITAXEL . An optional data collection (R1.1) will take place during the first cycle to collect actimetry data. And an optional data collection (R1.2) will take place 2 weeks after the theoretical end of PACLITAXEL in order to collect on file the grades of neuropathies and toxicities over the interval.

The visits will be carried out as part of the usual patient care.

Apart from the measurement of impedancemetry, grip strength, the chair rise test and actimetry, no other clinical, paraclinical intervention or biological analysis will be induced by the protocol.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sarcopenia Oncology Physical Inactivity Toxicity Due to Chemotherapy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Prospective cohort study

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Interventionnal

"Hand Grip" Dynamometer Chair rise test measurement of impedance SEFI Nutritional Intake Assessment Questionnaire GPAQ questionnaire SARC-F questionnaire

Group Type EXPERIMENTAL

Sarcopenia diagnostic test

Intervention Type DIAGNOSTIC_TEST

the study-specific measurements for the assessment of sarcopenia (impedancemetry, grip strength and chair rise test) as well as the distribution of actimeters to patients.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sarcopenia diagnostic test

the study-specific measurements for the assessment of sarcopenia (impedancemetry, grip strength and chair rise test) as well as the distribution of actimeters to patients.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients over 18 years old
* Patient with a diagnosis of a histologically proven solid malignant tumor with an indication for systemic treatment during initial treatment.
* CT/PET performed within 45 days before initiation of systemic treatment.
* Patient able to sign informed consent for participation in the study
* Patient affiliated to a social security system

Exclusion Criteria

* History of cancer in the five years preceding inclusion other than localized skin or cervical cancers.
* Patient with cancer not requiring systemic treatment.
* Pregnant women.
* Patient with a pace maker or defibrillator
* Patient deprived of liberty or benefiting from a legal protection measure

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No